However, head-to-head comparative studies of IL-23p19 subunit inhibitors versus other biologics for IBD are warranted to evaluate the relative efficacy of IL-23p19 subunit inhibitors versus other biologics. The gene discussed is IL23A; the disease is inflammatory bowel disease.